Your SlideShare is downloading. ×
  • Like
Flouroquinolones associated permanent nerve damage
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Now you can save presentations on your phone or tablet

Available for both IPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Flouroquinolones associated permanent nerve damage

  • 696 views
Published

FDA advises the manufacturers to update the label changes on Flouroquinolones associated peripheral neuropathy, on 15th Aug 13.

FDA advises the manufacturers to update the label changes on Flouroquinolones associated peripheral neuropathy, on 15th Aug 13.

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
696
On SlideShare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
6
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Flouroquinolones associated permanent nerve damage P.Naina Mohamed Pharmacologist
  • 2. Introduction  FDA has required the manufacturers on 15th Aug 13, to add the serious side effect of Peripheral neuropathy associated with fluoroquinolone antibacterial drugs, in to their drug labels and Medication Guides.  Approved fluoroquinolone drugs include Nevofloxacin, Ciprofloxacin, Moxifloxacin, Norfloxacin, Ofloxacin and Gemifloxacin.  Fluoroquinolones induced peripheral neuropathy may include symptoms in arms and legs such as dysesthesia (pain), burning, paresthesia (tingling), hypoesthesia (numbness), weakness and other sensorimotor problems.  This fluoroquinolones induced serious nerve damage, may occur soon after these drugs are taken and may be permanent.
  • 3. Fluoroquinolones  Structurally Quinolones contain a quinoline ring system and hence given the name quinolones.  Fluoroquinolones also contain a fluorine atom at the 6-position of the quinoline ring to increase the potency.  Fluoroquinolones and quinolones are not used for regular treatment of bacterial infections due to their severe side effects in rare cases.  They are generally used for more resistant strains of bacteria and are especially useful in genitourinary infections.
  • 4. Mechanism of Action Fluoroquinolones Bind to the A-subunit of DNA gyrase (topoisomerase II type) enzyme Prevents the binding of substrate to the active site of DNA gyrase Absence of formation of enzyme – substrate complex Blockade of unwinding of double-stranded DNA into a single stranded structure Prevention of synthesis of mRNA Inhibition of bacterial protein synthesis Antibacterial activity
  • 5. Gram-positive and Gram-negative bacterias  Gram-positive bacterias:  Fluoroquinolones inhibit DNA gyrase (topoisomerase II), which is responsible for supercoiling of gram-positive bacterial DNA during DNA replication.  Gram-negative bacterias:  But, in case of gram-negative bacteria, Fluoroquinolones inhibit topoisomerase IV, an enzyme responsible for relaxation of supercoiled circular DNA and separation of the inter-linked daughter chromosomes.
  • 6. Possible mechanism of toxicity Fluoroquinolones May induce axonal degeneration with secondary breakdown of the myelin sheath, or more rarely primary segmental demyelinisation Peripheral neuropathy
  • 7. Conclusion  Inform the patients to contact the healthcare professional, if they develop symptoms of peripheral neuropathy.  Ask the patients to read the Medication Guide with every prescription.  If a patient develops symptoms of peripheral neuropathy, the fluoroquinolone should be stopped, and the patient should be switched to another, non- fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk.
  • 8. References  http://www.fda.gov/Safety/MedWatch/SafetyInformation/S  http://www.ncbi.nlm.nih.gov/pubmed/11793615  http://jac.oxfordjournals.org/content/37/4/831.full.pdf  http://www.ncbi.nlm.nih.gov/pubmed/8722551  http://www.medscape.com/viewarticle/411159  http://www.ncbi.nlm.nih.gov/pubmed/10945507